Oragenics Inc. Secures U.S. Manufacturing Partner for Concussion Drug Ahead of Phase IIb Trials
Oragenics Inc. (NYSE American: OGEN), a biotechnology firm specializing in intranasal therapeutics for brain-related conditions, has announced a manufacturing agreement with Sterling Pharma Solutions. This partnership is for the Good Manufacturing Practice (GMP) production of ONP-002, Oragenics’ lead drug candidate aimed at treating concussions. The production will take place at Sterling’s facility in Cary, North […]